MOB Completions Drop 84% as Healthcare Real Estate Supply Dries Up

By Majid Radaei, RadCRE · 2026-11-09 · Market Updates

Medical outpatient completions plunged 84% below average in Q3 2026, tightening supply and driving institutional capital into healthcare assets.

Supply Constraints Reshape the Healthcare Real Estate Landscape

The medical outpatient building (MOB) sector is experiencing an unprecedented supply squeeze. According to research from CBRE, third-quarter completions fell 84% below the five-year average, dropping to just 264,000 square feet in Q3 2026 compared to just over 1 million square feet a year earlier [3]. This sharp retrenchment in new construction has altered market fundamentals across the sector. With tenant absorption holding steady and negligible new space coming online, vacancy rates are falling and rental rates are trending upward, prompting institutional investors to actively redeploy capital into outpatient assets [3].

Ten-Year Pipeline Lows and Tenant Demand Disconnect

The constriction in new supply is not limited to completed deliveries. Avison Young's national healthcare market analysis reveals that development starts have retreated to their lowest mark in at least a decade, with third-quarter construction starts dropping to 987,000 square feet [4]. Simultaneously, healthcare operators and clinical practices are leasing space at the fastest clip observed in nearly five years [4]. This dynamic has created what Avison Young terms a growing disconnect between strengthening leasing fundamentals and aggregate capital market volumes, pointing toward prolonged supply constraints that heavily favor existing healthcare facility owners [4].

Green Shoots Across the Life Sciences Sector

Paralleling the shifts in outpatient healthcare, the life sciences real estate sector is approaching an inflection point [2]. Following two years characterized by elevated supply, conservative corporate decision-making, and subdued capital markets activity, market conditions are stabilizing [2]. Construction pipelines are actively receding across primary life sciences clusters, tenant demand has reached a floor, and investors are re-engaging under more disciplined capital underwriting standards [2]. A structural combination of expiring pharmaceutical patents, accelerated innovation, and expanding domestic manufacturing requirements is reshaping laboratory and research space requirements heading through 2026 [2].

Global Capital Trends Highlight Outpatient and Clinical Portfolios

Cross-border institutional capital is increasingly targeting specialized healthcare infrastructure to capture these resilient fundamentals. In Europe and the wider EMEA region, JLL reports that healthcare investment reached €3.1 billion in Q3 2026, marking a 32% year-on-year increase and standing 9% above the historical five-year average [5]. Year-to-date transaction volume reached €10.4 billion, up 44% year-on-year, propelled by major portfolio recapitalizations that represented 85% of total volume [5]. Notably, Blue Owl Capital finalized a £1.3 billion (€1.5 billion) acquisition of a private hospital portfolio from Malaysia's Employees Provident Fund during the third quarter [5].

RadCRE Perspective

"The structural drop in construction completions—down 84% below five-year averages in the medical outpatient segment—creates an unmistakable operational runway for stabilized healthcare assets. When new deliveries fall to 264,000 square feet alongside decade-low construction starts, existing clinical and outpatient facilities capture pricing leverage that traditional office assets simply cannot match. For private and institutional owners, this supply drought marks the start of a landlord-favorable cycle driven by unavoidable demographic necessity."
— Majid Radaei, Founder & Principal Broker

Tags: medical office building investment, healthcare real estate trends, life sciences space demand, outpatient medical real estate